Patents by Inventor Matthias Barz

Matthias Barz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220001025
    Abstract: The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.
    Type: Application
    Filed: September 30, 2019
    Publication date: January 6, 2022
    Inventors: Matthias Barz, Benjamin Weber, Heinrich Haas, Philipp Heller, Sara Nogueira, Anne Schlegel
  • Publication number: 20210260203
    Abstract: There is provided novel polypeptide-based carrier systems, which make it possible to label polymeric nanoparticles in the living organism. This enables new approaches in tumor diagnostics (high signal to background ratio) and radiotherapy (radiotherapy of solid tumors).
    Type: Application
    Filed: June 26, 2019
    Publication date: August 26, 2021
    Inventors: Andreas KJÆR, Matthias Manfred HERTH, Matthias BARZ, Alexander Oksar BIRKE
  • Patent number: 9623125
    Abstract: Polyglutamates are well known to be highly biocompatible, biodegradable and multifunctional polymers, which have been already used as building blocks in polymer drug conjugates and polymeric micelles. Those systems have been applied to various medical applications ranging from therapy to molecular imaging. Furthermore a polyglutamic acid (PGA) paclitaxel conjugate has already entered clinical studies (Opaxio™ PGA-PTX conjugate currently in phase III of Clinical trials). In this context, a synthetic pathway to a plethora functional polyglutamates (homopolymers, block-co-polymers, tribocks) with well-defined structure, adjustable molecular weight (Mw) and low dispersity (D=Mw/Mn<1.2) applying the ring opening polymerization (ROP) of N-carboxyanhydrides (NCA) has been developed.
    Type: Grant
    Filed: October 23, 2012
    Date of Patent: April 18, 2017
    Assignee: Fundacion de la Comunidad Valenciana “Centro de Investigaciones Principe Felipe”
    Inventors: Maria Jesus Vicent Docon, Matthias Barz, Fabiana Canal, Inmaculada Conejos Sanchez, Aroa Duro Castano, Richard Mark England
  • Publication number: 20150087788
    Abstract: Polyglutamates are well known to be highly biocompatible, biodegradable and multifunctional polymers, which have been already used as building blocks in polymer drug conjugates and polymeric micelles. Those systems have been applied to various medical applications ranging from therapy to molecular imaging. Furthermore a polyglutamic acid (PGA) paclitaxel conjugate has already entered clinical studies (Opaxio™ PGA-PTX conjugate currently in phase III of Clinical trials). In this context, a synthetic pathway to a plethora functional polyglutamates (homopolymers, block-co-polymers, triblocks) with well-defined structure, adjustable molecular weight (Mw) and low dispersity (D=Mw/Mn<1.2) applying the ring opening polymerization (ROP) of N-carboxyanhydrides (NCA) has been developed.
    Type: Application
    Filed: October 23, 2012
    Publication date: March 26, 2015
    Inventors: Maria Jesus Vicent Docon, Matthias Barz, Fabiana Canal, Inmaculada Conejos Sanchez, Aroa Duro Castano, Richard Mark England